The global antipruritic market size is projected to surpass a valuation of USD 16.2 billion by 2034. Our healthcare analysts opine that antipruritic manufacturers can expect a CAGR of 4.2% through 2034, with a current valuation of USD 10.9 billion in 2024.
| Attributes | Market Insights |
|---|---|
| Market Value 2023 | USD 10.5 billion |
| Market Value 2024 | USD 10.9 billion |
| Market Value 2034 | USD 16.2 billion |
| CAGR 2024 to 2034 | 4.2% |
| Market Share of Top 5 Countries | 60.8% |
Pruritus is a complex process that frequently happens with skin conditions, including atopic dermatitis and urticaria, and may harm quality of life. Additionally, it might be a sign of an underlying medical condition, such as hyperthyroidism or cholestasis, or it might just be the result of dry skin, especially during the chilly winter months.
Therapy focuses on treating the itching first, then addressing the underlying cause. Herbal therapies, prescription and over-the-counter (OTC) drugs, hydrotherapy, phototherapy, and UV therapy are all possible forms of treatment.
Key Market Highlights:
| Attributes | Details |
|---|---|
| Antipruritic Market Size (2019) | USD 9.1 billion |
| Antipruritic Market Size (2023) | USD 10.5 billion |
| Antipruritic Market CAGR (2019 to 2023) | 4.1% |
The market observed a growth of 4.1% during 2019 and 2023. The global market for antipruritic held nearly 64.6% of the overall USD 15.7 billion skin treatment market shares in 2023.
The most frequent dermatologic symptom reported by patients is pruritus. It is associated with a variety of skin conditions, the majority of which are characterized by primary lesions such as vesicles, plaques, and papules.
The underlying causes of pruritus are still unknown, making it difficult for healthcare practitioners to control itching in individuals with severe pruritus adequately. There are typically discrepancies between causative and symptomatic approaches to pruritus therapy. A common strategy for navigating the broad terrain of pruritus therapy is to categorize these alternatives according to their underlying causes.
Causative therapy aims to identify and treat the underlying illness causing the itching. Symptomatic treatment hides the itch through treatments such as cooling, heating, or counter-irritation (e.g., scratching). To provide relief sooner, symptomatic treatment and addressing the underlying disease process may be used. The popular therapeutic options are classified as symptomatic therapy and management.
Disruptive technical advancements, increasing healthcare investments, and health system optimization are driving the swift development of the medical and drug industries. Modern medical institutions, ambulatory care centers, and clinics throughout the world are deliberately adopting cutting-edge technological technologies and equipment into their operations to improve efficiency and competitiveness.
The global market's revenue growth is fuelled by factors such as rising chronic illness incidence, rapid improvements in the healthcare and medical sectors, widespread use of new instruments and techniques, and increased funding from various public and private sectors.
Furthermore, rising emphasis on drug discovery, rising need for precision medicine, widespread deployment of home care services and point-of-care diagnostics, and increased investments in R&D activities are likely to boost global market revenue and profit during the projected timeframe.
These factors are projected to impact the growth of the industry worldwide positively. With a CAGR of 4.2%, the industry is predicted to develop significantly during the following decade.
Chronic pruritus, a growing health problem, significantly impacts quality of life. Ongoing research has revealed new pathways and itch receptors, which has improved our understanding of these aspects. Expectations are strong that these latest insights are going to encourage the development of ground-breaking treatments for this frequently ignored and inconvenient ailment.
The administration of medications that reduce neural sensitization to pain, such as gabapentin, pregabalin, SSRIs, and norepinephrine antidepressants, either singly or in combination, is now required for the therapeutic management of chronic pruritus.
In the future, adopting a variety of topical and systemic medicines that focus on the different receptors and neurological pathways mediating distinct forms of itch would improve the quality of life for millions of pruritic patients.
Because of the condition's complex etiology and various contributing factors, treating chronic pruritus (CP) remains challenging. Despite the well-known antipruritic properties of traditional pharmacotherapy, such as topical therapy, light therapy, and systemic therapy, these strategies typically fail to provide significant relief for affected individuals.
Despite the wide range of therapy options, chronic pruritus is still challenging to treat. Several antipruritic treatments are still used off-label as of right now. There are currently just a few effective topical treatments for itching, and existing itch management techniques do not cover most unmet needs.
Furthermore, few published works employ general health metrics to evaluate CP, and there are very few economic statistics on the cost of chronic pruritus. According to the American Academy of Dermatology's (AAD) National Burden of Skin Disease report, pruritus-related disorders in the United States incur a yearly treatment expense of USD 294 million and an opportunity cost of USD 107 million (2017).
According to Luk et al. (2020), people with CP have an annual financial burden of USD 1,067 because of both direct and secondary medical costs. The impact of stress, anxiety, depression, and functional incapacity on the patient and their loved ones as a result of the condition are examples of what are known as intangible costs that are not taken into account by current techniques of cost assessment.
During the forecast period, the market is expected to experience barriers in its growth trajectory due to a significant financial burden, limited evidence-based data, and parameters associated with existing treatment alternatives.
| Countries | CAGR (2024 to 2034) |
|---|---|
| United States | 37.4% |
| China | 8.9% |
| Germany | 4.70% |
| United Kingdom | 5.10% |
| Japan | 3.20% |
The United States dominated the antipruritic market with 37.4% of market shares in 2023. The antipruritic market size in the United States is estimated to rise at a 4.30% CAGR through 2034. The country has a vast healthcare system includes comprehensive patient care and reimbursement provisions. Moreover, with greater patient awareness regarding various treatment modalities and options for pruritus treatments, the country holds a leading stance within the global market.
China captured a value share of 8.9% in the global market in 2023. The demand for antipruritic treatments is projected to surge at a 6.90% CAGR through 2034. It has been observed in several population-based studies that in Chinese patients, the frequency and severity of pruritus vary with skin conditions, skin type, age, and gender.
According to GBD 2019, young and middle-aged demographics have a higher illness burden from acne. Nearly 9.4% of the world’s population suffers from acne, making it the 8th most widespread condition globally. The market for antipruritics is driven by the increased prevalence of skin diseases in China, providing key producers with opportunities to expand within the country.
Germany held around 5.7% of the antipruritic market in 2023. The market for antipruritic in Germany is predicted to thrive at a 4.70% CAGR through 2034. In Germany, a surprisingly high number of pruritus sufferers, particularly those with specific localizations on the body, have unmet medical needs. This factor promotes opportunities for established manufacturers within the country to promote and develop novel therapeutics, addressing these unmet needs, hence propelling growth throughout the forecast period.
The United Kingdom held nearly 3.50% of the market shares in 2023. The demand for antipruritic in the United Kingdom is estimated to rise at a 5.10% CAGR through 2034. The introduction of telemedicine services in the United Kingdom has unlocked the door to online consultations and prescriptions for antipruritic drugs, increasing access to healthcare services. Government subsidies or incentives for research and development could appeal to pharmaceutical businesses to invest in producing new and improved antipruritic remedies.
Japan held nearly 5.20% of the market shares in 2023. The antipruritic market size in Japan is projected to surge at a 3.20% CAGR through 2034. Skincare and appearance are highly valued in Japanese society. A robust cultural preference for preserving good skin increases demand for antipruritic treatments, particularly those with aesthetic advantages. Japan is famous for its technological advances. Integration of cutting-edge technology, such as smart skincare devices or AI-driven diagnostic tools for dermatological diseases, could represent a differentiating element in market growth.
| Segment | Immunosuppressants (Drug Type) |
|---|---|
| Value Share (2024) | 31.3% |
Immunosuppressants held a share of around 31.3% in the global market in 2023. This is due to the effectiveness of oral immunosuppressants such as cyclosporine, mycophenolate mofetil, and azathioprine in treating itching caused by inflammatory disorders like atopic dermatitis. Furthermore, systemic corticosteroids can also be administered to reduce inflammation in extreme situations of chronic pruritus.
The most effective way to reduce itching in atopic dermatitis is to manage the inflammation with topical or systemic immunosuppressive medications effectively.
| Segment | Psoriasis (Disease Type) |
|---|---|
| Value Share (2024) | 33.2% |
Psoriasis held around 33.2% of the global market in 2023. Psoriasis is a prevalent, chronic illness that has no cure. According to the 2019 report on the worldwide disease burden, there have been 4,622,594 reported cases of psoriasis globally in that year. The age range of 60 to 69 years has the maximum prevalence of psoriasis overall, with a roughly equal frequency between men and women.
The burden is substantially heavier in North American and European countries with high incomes and high SDI indices. To help reduce the disease burden of psoriasis globally, this factor fuels the interest of manufacturers in the market in the development of novel therapies.
| Segment | Oral (Route of Administration) |
|---|---|
| Value Share (2024) | 39.8% |
The oral route of administration held a share of around 39.8% in the global market in 2023. This is due to the usage of oral antihistamines for the symptomatic alleviation of pruritus. Oral antihistamines of the first or second generations, such as cetirizine and loratadine, are widely recommended. First-generation oral antihistamines include diphenhydramine and hydroxyzine.
Moreover, due to the ease of administration of oral medication dosages, the oral route of administration gains a more significant share within the global market.
| Segment | Hospital Pharmacies (Distribution Channel) |
|---|---|
| Value Share (2024) | 30.4% |
Hospital pharmacies held around 30.4% of the global market in 2023. Several institutional pharmacies provide commonly prescribed medications for pruritus at subsidized rates, thus propelling sales of antipruritics within these settings. Moreover, with the ease of dispensing, presence of branded and generic drug options, as well as greater accessibility to patients, this segment holds a dominant share within the global market.
Key players are enhancing their research and development activities to launch novel products. The expansion of their product range and efforts to improve their pipelined products are two other strategic acquisitions and partnerships with key businesses.
Recent Developments
| Attribute | Details |
|---|---|
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2019 to 2023 |
| Market Analysis | USD billion for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, the Middle East and Africa (MEA) |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, Spain, United Kingdom, Russia, BENELUX, China, Japan, South Korea, India, Indonesia, Thailand, Malaysia, Australia, New Zealand, GCC Countries, Turkey, North Africa, South Africa |
| Key Companies Covered | AbbVie Inc.; Allergan, Merck & Co., Inc.; Amgen Inc.; Pfizer Inc.; Cara Therapeutics; Enteris BioPharma; NeRRe Therapeutics; Menlo Therapeutics; XBiotech Inc.; Ipsen Pharma; Eledon Pharmaceuticals, Inc.; Amorepacific; RDD Pharma, Ltd; Novartis AG; AstraZeneca; Sanofi; Sun Pharmaceutical Industries Ltd.; Teva Pharmaceutical Industries Ltd.; Takeda Pharmaceutical Company Limited; Cipla Ltd. |
| Key Market Segments Covered | Drug, Disease, Route of Administration, Distribution Channel, and Region |
| Pricing | Available upon Request |
Table 01: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug
Table 02: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Disease
Table 03: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Route of Administration
Table 04: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel
Table 05: Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region
Table 06: North America Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 07: North America Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug
Table 08: North America Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Disease
Table 09: North America Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Route of Administration
Table 10: North America Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel
Table 11: Latin America Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 12: Latin America Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug
Table 13: Latin America Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Disease
Table 14: Latin America Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Route of Administration
Table 15: Latin America Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel
Table 16: Europe Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 17: Europe Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug
Table 18: Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Disease
Table 19: Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Route of Administration
Table 20: Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel
Table 21: East Asia Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 22: East Asia Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug
Table 23: East Asia Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Disease
Table 24: East Asia Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Route of Administration
Table 25: East Asia Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel
Table 26: South Asia Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 27: South Asia Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug
Table 28: South Asia Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Disease
Table 29: South Asia Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Route of Administration
Table 30: South Asia Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel
Table 31: Oceania Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 32: Oceania Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug
Table 33: Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Disease
Table 34: Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Route of Administration
Table 35: Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel
Table 36: Middle East & Africa Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 37: Middle East & Africa Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug
Table 38: Middle East & Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Disease
Table 39: Middle East & Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Route of Administration
Table 40: Middle East & Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution ChannelValue (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug
Table 33: Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Disease
Table 34: Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Route of Administration
Table 35: Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel
Table 36: Middle East & Africa Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
Table 37: Middle East & Africa Value (US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug
Table 38: Middle East & Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Disease
Table 39: Middle East & Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Route of Administration
Table 40: Middle East & Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Distribution Channel
Figure 01: Global Market Value (US$ Million) Analysis, 2017 to 2022
Figure 02: Global Market Forecast & Y-o-Y Growth, 2023 to 2033
Figure 03: Global Market Absolute $ Opportunity (US$ Million) Analysis, 2022 to 2033
Figure 04: Global Market Value Share (%) Analysis 2023 and 2033, by Drug
Figure 05: Global Market Y-o-Y Growth (%) Analysis 2022-2033, by Drug
Figure 06: Global Market Attractiveness Analysis 2023 to 2033, by Drug
Figure 07: Global Market Value Share (%) Analysis 2023 and 2033, by Disease
Figure 08: Global Market Y-o-Y Growth (%) Analysis 2022-2033, by Disease
Figure 09: Global Market Attractiveness Analysis 2023 to 2033, by Disease
Figure 10: Global Market Value Share (%) Analysis 2023 and 2033, by Route of Administration
Figure 11: Global Market Y-o-Y Growth (%) Analysis 2022-2033, by Route of Administration
Figure 12: Global Market Attractiveness Analysis 2023 to 2033, by Route of Administration
Figure 13: Global Market Value Share (%) Analysis 2023 and 2033, by Distribution Channel
Figure 14: Global Market Y-o-Y Growth (%) Analysis 2022-2033, by Distribution Channel
Figure 15: Global Market Attractiveness Analysis 2023 to 2033, by Distribution Channel
Figure 16: Global Market Value Share (%) Analysis 2023 and 2033, by Region
Figure 17: Global Market Y-o-Y Growth (%) Analysis 2022-2033, by Region
Figure 18: Global Market Attractiveness Analysis 2023 to 2033, by Region
Figure 19: North America Value (US$ Million) Analysis, 2017 to 2022
Figure 20: North America Value (US$ Million) Forecast, 2023-2033
Figure 21: North America Value Share, by Drug (2023 E)
Figure 22: North America Value Share, by Disease (2023 E)
Figure 23: North America Value Share, by Route of Administration (2023 E)
Figure 24: North America Value Share, by Distribution Channel (2023 E)
Figure 25: North America Value Share, by Country (2023 E)
Figure 26: North America Attractiveness Analysis by Drug, 2023 to 2033
Figure 27: North America Attractiveness Analysis by Disease, 2023 to 2033
Figure 28: North America Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 29: North America Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 30: North America Attractiveness Analysis by Country, 2023 to 2033
Figure 31: USA Value Proportion Analysis, 2022
Figure 32: Global Vs. USA Growth Comparison
Figure 33: USA Share Analysis (%) by Drug, 2022 to 2033
Figure 34: USA Share Analysis (%) by Disease, 2022 to 2033
Figure 35: USA Share Analysis (%) by Route of Administration, 2022 to 2033
Figure 36: USA Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 37: Canada Value Proportion Analysis, 2022
Figure 38: Global Vs. Canada. Growth Comparison
Figure 39: Canada Share Analysis (%) by Drug, 2022 to 2033
Figure 40: Canada Share Analysis (%) by Disease, 2022 to 2033
Figure 41: Canada Share Analysis (%) by Route of Administration, 2022 to 2033
Figure 42: Canada Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 43: Latin America Value (US$ Million) Analysis, 2017 to 2022
Figure 44: Latin America Value (US$ Million) Forecast, 2023-2033
Figure 45: Latin America Value Share, by Drug (2023 E)
Figure 46: Latin America Value Share, by Disease (2023 E)
Figure 47: Latin America Value Share, by Route of Administration (2023 E)
Figure 48: Latin America Value Share, by Distribution Channel (2023 E)
Figure 49: Latin America Value Share, by Country (2023 E)
Figure 50: Latin America Attractiveness Analysis by Drug, 2023 to 2033
Figure 51: Latin America Attractiveness Analysis by Disease, 2023 to 2033
Figure 52: Latin America Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 53: Latin America Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 54: Latin America Attractiveness Analysis by Country, 2023 to 2033
Figure 55: Mexico Value Proportion Analysis, 2022
Figure 56: Global Vs Mexico Growth Comparison
Figure 57: Mexico Share Analysis (%) by Drug, 2022 to 2033
Figure 58: Mexico Share Analysis (%) by Disease, 2022 to 2033
Figure 59: Mexico Share Analysis (%) by Route of Administration, 2022 to 2033
Figure 60: Mexico Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 61: Brazil Value Proportion Analysis, 2022
Figure 62: Global Vs. Brazil. Growth Comparison
Figure 63: Brazil Share Analysis (%) by Drug, 2022 to 2033
Figure 64: Brazil Share Analysis (%) by Disease, 2022 to 2033
Figure 65: Brazil Share Analysis (%) by Route of Administration, 2022 to 2033
Figure 66: Brazil Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 67: Argentina Value Proportion Analysis, 2022
Figure 68: Global Vs Argentina Growth Comparison
Figure 69: Argentina Share Analysis (%) by Drug, 2022 to 2033
Figure 70: Argentina Share Analysis (%) by Disease, 2022 to 2033
Figure 71: Argentina Share Analysis (%) by Route of Administration, 2022 to 2033
Figure 72: Argentina Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 73: Europe Value (US$ Million) Analysis, 2017 to 2022
Figure 74: Europe Value (US$ Million) Forecast, 2023-2033
Figure 75: Europe Value Share, by Drug (2023 E)
Figure 76: Europe Value Share, by Disease (2023 E)
Figure 77: Europe Value Share, by Route of Administration (2023 E)
Figure 78: Europe Value Share, by Distribution Channel (2023 E)
Figure 79: Europe Value Share, by Country (2023 E)
Figure 80: Europe Attractiveness Analysis by Drug, 2023 to 2033
Figure 81: Europe Attractiveness Analysis by Disease, 2023 to 2033
Figure 82: Europe Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 83: Europe Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 84: Europe Attractiveness Analysis by Country, 2023 to 2033
Figure 85: UK Value Proportion Analysis, 2022
Figure 86: Global Vs. UK Growth Comparison
Figure 87: UK Share Analysis (%) by Drug, 2022 to 2033
Figure 88: UK Share Analysis (%) by Disease, 2022 to 2033
Figure 89: UK Share Analysis (%) by Route of Administration, 2022 to 2033
Figure 90: UK Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 91: Germany Value Proportion Analysis, 2022
Figure 92: Global Vs. Germany Growth Comparison
Figure 93: Germany Share Analysis (%) by Drug, 2022 to 2033
Figure 94: Germany Share Analysis (%) by Disease, 2022 to 2033
Figure 95: Germany Share Analysis (%) by Route of Administration, 2022 to 2033
Figure 96: Germany Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 97: Italy Value Proportion Analysis, 2022
Figure 98: Global Vs. Italy Growth Comparison
Figure 99: Italy Share Analysis (%) by Drug, 2022 to 2033
Figure 100: Italy Share Analysis (%) by Disease, 2022 to 2033
Figure 101: Italy Share Analysis (%) by Route of Administration, 2022 to 2033
Figure 102: Italy Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 103: France Value Proportion Analysis, 2022
Figure 104: Global Vs France Growth Comparison
Figure 105: France Share Analysis (%) by Drug, 2022 to 2033
Figure 106: France Share Analysis (%) by Disease, 2022 to 2033
Figure 107: France Share Analysis (%) by Route of Administration, 2022 to 2033
Figure 108: France Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 109: Spain Value Proportion Analysis, 2022
Figure 110: Global Vs Spain Growth Comparison
Figure 111: Spain Share Analysis (%) by Drug, 2022 to 2033
Figure 112: Spain Share Analysis (%) by Disease, 2022 to 2033
Figure 113: Spain Share Analysis (%) by Route of Administration, 2022 to 2033
Figure 114: Spain Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 115: Russia Value Proportion Analysis, 2022
Figure 116: Global Vs Russia Growth Comparison
Figure 117: Russia Share Analysis (%) by Drug, 2022 to 2033
Figure 118: Russia Share Analysis (%) by Disease, 2022 to 2033
Figure 119: Russia Share Analysis (%) by Route of Administration, 2022 to 2033
Figure 120: Russia Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 121: BENELUX Value Proportion Analysis, 2022
Figure 122: Global Vs BENELUX Growth Comparison
Figure 123: BENELUX Share Analysis (%) by Drug, 2022 to 2033
Figure 124: BENELUX Share Analysis (%) by Disease, 2022 to 2033
Figure 125: BENELUX Share Analysis (%) by Route of Administration, 2022 to 2033
Figure 126: BENELUX Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 127: East Asia Value (US$ Million) Analysis, 2017 to 2022
Figure 128: East Asia Value (US$ Million) Forecast, 2023-2033
Figure 129: East Asia Value Share, by Drug (2023 E)
Figure 130: East Asia Value Share, by Disease (2023 E)
Figure 131: East Asia Value Share, by Route of Administration (2023 E)
Figure 132: East Asia Value Share, by Distribution Channel (2023 E)
Figure 133: East Asia Value Share, by Country (2023 E)
Figure 134: East Asia Attractiveness Analysis by Drug, 2023 to 2033
Figure 135: East Asia Attractiveness Analysis by Disease, 2023 to 2033
Figure 136: East Asia Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 137: East Asia Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 138: East Asia Attractiveness Analysis by Country, 2023 to 2033
Figure 139: China Value Proportion Analysis, 2022
Figure 140: Global Vs. China Growth Comparison
Figure 141: China Share Analysis (%) by Drug, 2022 to 2033
Figure 142: China Share Analysis (%) by Disease, 2022 to 2033
Figure 143: China Share Analysis (%) by Route of Administration, 2022 to 2033
Figure 144: China Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 145: Japan Value Proportion Analysis, 2022
Figure 146: Global Vs. Japan Growth Comparison
Figure 147: Japan Share Analysis (%) by Drug, 2022 to 2033
Figure 148: Japan Share Analysis (%) by Disease, 2022 to 2033
Figure 149: Japan Share Analysis (%) by Route of Administration, 2022 to 2033
Figure 150: Japan Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 151: South Korea Value Proportion Analysis, 2022
Figure 152: Global Vs South Korea Growth Comparison
Figure 153: South Korea Share Analysis (%) by Drug, 2022 to 2033
Figure 154: South Korea Share Analysis (%) by Disease, 2022 to 2033
Figure 155: South Korea Share Analysis (%) by Route of Administration, 2022 to 2033
Figure 156: South Korea Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 157: South Asia Value (US$ Million) Analysis, 2017 to 2022
Figure 158: South Asia Value (US$ Million) Forecast, 2023-2033
Figure 159: South Asia Value Share, by Drug (2023 E)
Figure 160: South Asia Value Share, by Disease (2023 E)
Figure 161: South Asia Value Share, by Route of Administration (2023 E)
Figure 162: South Asia Value Share, by Distribution Channel (2023 E)
Figure 163: South Asia Value Share, by Country (2023 E)
Figure 164: South Asia Attractiveness Analysis by Drug, 2023 to 2033
Figure 165: South Asia Attractiveness Analysis by Disease, 2023 to 2033
Figure 166: South Asia Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 167: South Asia Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 168: South Asia Attractiveness Analysis by Country, 2023 to 2033
Figure 169: India Value Proportion Analysis, 2022
Figure 170: Global Vs. India Growth Comparison
Figure 171: India Share Analysis (%) by Drug, 2022 to 2033
Figure 172: India Share Analysis (%) by Disease, 2022 to 2033
Figure 173: India Share Analysis (%) by Route of Administration, 2022 to 2033
Figure 174: India Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 175: Indonesia Value Proportion Analysis, 2022
Figure 176: Global Vs. Indonesia Growth Comparison
Figure 177: Indonesia Share Analysis (%) by Drug, 2022 to 2033
Figure 178: Indonesia Share Analysis (%) by Disease, 2022 to 2033
Figure 179: Indonesia Share Analysis (%) by Route of Administration, 2022 to 2033
Figure 180: Indonesia Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 181: Malaysia Value Proportion Analysis, 2022
Figure 182: Global Vs. Malaysia Growth Comparison
Figure 183: Malaysia Share Analysis (%) by Drug, 2022 to 2033
Figure 184: Malaysia Share Analysis (%) by Disease, 2022 to 2033
Figure 185: Malaysia Share Analysis (%) by Route of Administration, 2022 to 2033
Figure 186: Malaysia Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 187: Thailand Value Proportion Analysis, 2022
Figure 188: Global Vs. Thailand Growth Comparison
Figure 189: Thailand Share Analysis (%) by Drug, 2022 to 2033
Figure 190: Thailand Share Analysis (%) by Disease, 2022 to 2033
Figure 191: Thailand Share Analysis (%) by Route of Administration, 2022 to 2033
Figure 192: Thailand Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 193: Oceania Value (US$ Million) Analysis, 2017 to 2022
Figure 194: Oceania Value (US$ Million) Forecast, 2023-2033
Figure 195: Oceania Value Share, by Drug (2023 E)
Figure 196: Oceania Value Share, by Disease (2023 E)
Figure 197: Oceania Value Share, by Route of Administration (2023 E)
Figure 198: Oceania Value Share, by Distribution Channel (2023 E)
Figure 199: Oceania Value Share, by Country (2023 E)
Figure 200: Oceania Attractiveness Analysis by Drug, 2023 to 2033
Figure 201: Oceania Attractiveness Analysis by Disease, 2023 to 2033
Figure 202: Oceania Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 203: Oceania Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 204: Oceania Attractiveness Analysis by Country, 2023 to 2033
Figure 205: Australia Value Proportion Analysis, 2022
Figure 206: Global Vs. Australia Growth Comparison
Figure 207: Australia Share Analysis (%) by Drug, 2022 to 2033
Figure 208: Australia Share Analysis (%) by Disease, 2022 to 2033
Figure 209: Australia Share Analysis (%) by Route of Administration, 2022 to 2033
Figure 210: Australia Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 211: New Zealand Value Proportion Analysis, 2022
Figure 212: Global Vs New Zealand Growth Comparison
Figure 213: New Zealand Share Analysis (%) by Drug, 2022 to 2033
Figure 214: New Zealand Share Analysis (%) by Disease, 2022 to 2033
Figure 215: New Zealand Share Analysis (%) by Route of Administration, 2022 to 2033
Figure 216: New Zealand Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 217: Middle East & Africa Value (US$ Million) Analysis, 2017 to 2022
Figure 218: Middle East & Africa Value (US$ Million) Forecast, 2023-2033
Figure 219: Middle East & Africa Value Share, by Drug (2023 E)
Figure 220: Middle East & Africa Value Share, by Disease (2023 E)
Figure 221: Middle East & Africa Value Share, by Route of Administration (2023 E)
Figure 222: Middle East & Africa Value Share, by Distribution Channel (2023 E)
Figure 223: Middle East & Africa Value Share, by Country (2023 E)
Figure 224: Middle East & Africa Attractiveness Analysis by Drug, 2023 to 2033
Figure 225: Middle East & Africa Attractiveness Analysis by Disease, 2023 to 2033
Figure 226: Middle East & Africa Attractiveness Analysis by Route of Administration, 2023 to 2033
Figure 227: Middle East & Africa Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 228: Middle East & Africa Attractiveness Analysis by Country, 2023 to 2033
Figure 229: GCC Countries Value Proportion Analysis, 2022
Figure 230: Global Vs GCC Countries Growth Comparison
Figure 231: GCC Countries Share Analysis (%) by Drug, 2022 to 2033
Figure 232: GCC Countries Share Analysis (%) by Disease, 2022 to 2033
Figure 233: GCC Countries Share Analysis (%) by Route of Administration, 2022 to 2033
Figure 234: GCC Countries Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 235: Türkiye Value Proportion Analysis, 2022
Figure 236: Global Vs. Türkiye Growth Comparison
Figure 237: Türkiye Share Analysis (%) by Drug, 2022 to 2033
Figure 238: Türkiye Share Analysis (%) by Disease, 2022 to 2033
Figure 239: Türkiye Share Analysis (%) by Route of Administration, 2022 to 2033
Figure 240: Türkiye Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 241: South Africa Value Proportion Analysis, 2022
Figure 242: Global Vs. South Africa Growth Comparison
Figure 243: South Africa Share Analysis (%) by Drug, 2022 to 2033
Figure 244: South Africa Share Analysis (%) by Disease, 2022 to 2033
Figure 245: South Africa Share Analysis (%) by Route of Administration, 2022 to 2033
Figure 246: South Africa Share Analysis (%) by Distribution Channel, 2022 to 2033
Figure 247: North Africa Value Proportion Analysis, 2022
Figure 248: Global Vs North Africa Growth Comparison
Figure 249: North Africa Share Analysis (%) by Drug, 2022 to 2033
Figure 250: North Africa Share Analysis (%) by Disease, 2022 to 2033
Figure 251: North Africa Share Analysis (%) by Route of Administration, 2022 to 2033
Figure 252: North Africa Share Analysis (%) by Distribution Channel, 2022 to 2033
The global antipruritic market is worth USD 10.9 billion in 2024.
The market is expected to reach USD 16.2 billion by the end of 2034 at a CAGR of 4.2%.
The growing geriatric population, rising burden of skin diseases, and rising R&D on novel biopharmaceuticals.
The antipruritic market in East Asia and Latin America is expanding at 4.7% CAGR.
Europe is projected to develop with a CAGR of 4.2% during the forecast period.
The United States, the United Kingdom, China, Japan, and Germany are the top five countries in the market.
AbbVie Inc., Allergan, Merck & Co., Inc., and Pfizer Inc. are some key players in the antipruritics industry.
From 2019 to 2023, the antipruritics market expanded at a 4.1% CAGR.
Antipruritic Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
